Onconova Therapeutics (NASDAQ:ONTX) Stock Rating Reaffirmed by Noble Financial

Onconova Therapeutics (NASDAQ:ONTXGet Rating)‘s stock had its “buy” rating reissued by equities research analysts at Noble Financial in a research report issued on Thursday, TipRanks reports. They presently have a $11.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on ONTX. LADENBURG THALM/SH SH assumed coverage on shares of Onconova Therapeutics in a report on Tuesday, March 1st. They issued a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research raised shares of Onconova Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Wednesday, March 23rd. Finally, StockNews.com initiated coverage on shares of Onconova Therapeutics in a report on Tuesday. They issued a “hold” rating for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $8.00.

ONTX stock opened at $1.08 on Thursday. Onconova Therapeutics has a twelve month low of $1.00 and a twelve month high of $16.50. The company’s 50 day moving average is $1.59 and its two-hundred day moving average is $2.19. The stock has a market cap of $22.57 million, a P/E ratio of -1.29 and a beta of 1.80.

Onconova Therapeutics (NASDAQ:ONTXGet Rating) last released its quarterly earnings data on Wednesday, May 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Onconova Therapeutics had a negative return on equity of 38.96% and a negative net margin of 7,151.77%. During the same quarter last year, the firm posted ($0.30) EPS. On average, equities analysts predict that Onconova Therapeutics will post -0.76 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. CVI Holdings LLC acquired a new stake in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Pura Vida Investments LLC acquired a new stake in Onconova Therapeutics in the third quarter valued at about $575,000. GSA Capital Partners LLP purchased a new stake in Onconova Therapeutics in the 3rd quarter valued at approximately $922,000. Geode Capital Management LLC increased its position in Onconova Therapeutics by 24.1% during the 3rd quarter. Geode Capital Management LLC now owns 177,430 shares of the biopharmaceutical company’s stock worth $679,000 after purchasing an additional 34,450 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Onconova Therapeutics by 140.8% during the 1st quarter. Renaissance Technologies LLC now owns 321,743 shares of the biopharmaceutical company’s stock worth $592,000 after buying an additional 188,116 shares in the last quarter. Institutional investors own 11.53% of the company’s stock.

About Onconova Therapeutics (Get Rating)

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer.

Further Reading

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.